TCN2 and obstructive sleep apnea syndrome: The dual association of both increased TCN2 expression (in OSA tumors) and increased circulatory APO-TCN2 levels (in OSA peripheral blood plasma) with improved patient outcome provides credence to our findings and this biomarker’s future clinical utility in this disease.